Figure 5.

KAR Progress through the Secretory Pathway Is Regulated by Transient KAR Stimulation

(A) Representative images of SBP-EGFP-GluK2 without biotin (0), with biotin for 30 min (30), or with a transient 5-min pre-treatment with 10 μM kainate before biotin addition (30+KA). Total SBP-EGFP-GluK2 was visualized with EGFP, and the surface-expressed SBP-EGFP-GluK2 was live-labeled with anti-SBP.

(B) Quantification of five independent experiments (n = 24–40). ^∗∗∗∗p < 0.0001, Welch’s t test.

(C) Representative images of SBP-EGFP-GluA1 without biotin (0), with biotin for 45 min (45), or with a transient 5-min pre-treatment with 10 μM kainate before biotin addition (45+KA). Total SBP-EGFP-GluA1 was visualized with EGFP, and the surface-expressed SBP-EGFP-GluA1 was live-labeled with anti-SBP antibody.

(D) Quantification of three independent experiments; n = 24 for all conditions. p > 0.05, Welch’s t test.

(E) Representative images of SBP-EGFP-GluK2 S846A/S868A, 30 min after biotin (AA 30), or with a transient 5-min pre-treatment with kainate before biotin addition (AA 30+KA). Total SBP-EGFP-GluK2 S846A/S868A was visualized with EGFP, and surface-expressed SBP-EGFP-GluK2 S846A/S868A was live-labeled with anti-SBP antibody.

(F) Quantification of three independent experiments; n = 15–30. ^∗∗∗∗p < 0.0001, ^∗∗∗p < 0.001, Welch’s t test.

Scale bars, 10 μm.